Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying α-Synuclein–Containing Extracellular Vesicles
暂无分享,去创建一个
T. Montine | J. Quinn | E. Peskind | Tessandra H Stewart | Min Shi | Lifu Sheng | Jing Zhang | C. Zabetian | J. Aasly | C. Pan | K. Borden | Chen Tian | Patrick Aro | Zhen Hong | David Soltys | Tarek Khrisat | Matt Bercow | Tessandra H. Stewart
[1] J. Quinn,et al. Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson’s disease pathogenesis , 2020, Acta Neuropathologica Communications.
[2] S. Morgello,et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles reveals synaptic injury, inflammation, and stress response markers in HIV patients with cognitive impairment , 2019, Journal of Neuroinflammation.
[3] T. Feng,et al. Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease , 2019, Translational Neurodegeneration.
[4] Claudio Soto,et al. Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[5] Tessandra H Stewart,et al. New windows into the brain: Central nervous system-derived extracellular vesicles in blood , 2019, Progress in Neurobiology.
[6] J. Trojanowski,et al. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease , 2018, Alzheimer's & Dementia.
[7] P. Jensen,et al. ELISA method to detect α-synuclein oligomers in cell and animal models , 2018, PloS one.
[8] J. Lötvall,et al. A rapid, automated surface protein profiling of single circulating exosomes in human blood , 2016, Scientific Reports.
[9] Kathleen F. Kerr,et al. CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease , 2016, Alzheimer's & Dementia.
[10] Imre Mäger,et al. Extracellular vesicles in neurodegenerative disease — pathogenesis to biomarkers , 2016, Nature Reviews Neurology.
[11] Hong-Jian Zhu,et al. Extracellular vesicle isolation and characterization: toward clinical application. , 2016, The Journal of clinical investigation.
[12] Arthur W. Toga,et al. CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study , 2016, Acta Neuropathologica.
[13] Takahiko Tokuda,et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.
[14] T. Montine,et al. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease , 2015, Journal of neuropathology and experimental neurology.
[15] V. Sossi,et al. Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity , 2015, Acta neuropathologica communications.
[16] I. Sargent,et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing , 2014, Journal of thrombosis and haemostasis : JTH.
[17] A. Schapira. Recent developments in biomarkers in Parkinson disease , 2013, Current opinion in neurology.
[18] E. Tolosa,et al. Parkinson disease: New guidelines for diagnosis of Parkinson disease , 2013, Nature Reviews Neurology.
[19] K. Blennow,et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.
[20] Yu Wang,et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.
[21] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[22] Philip L De Jager,et al. Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.
[23] T G van Leeuwen,et al. Optical and non‐optical methods for detection and characterization of microparticles and exosomes , 2010, Journal of thrombosis and haemostasis : JTH.
[24] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[25] D. Galasko,et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. , 2010, Archives of neurology.
[26] Aneeka M Hancock,et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.
[27] Y. Allory,et al. The L1 cell adhesion molecule is a potential biomarker of human distal nephron injury in acute tubular necrosis. , 2008, Kidney international.
[28] E. Tolosa,et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[29] Aled Clayton,et al. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.
[30] Andrew J. Lees,et al. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.
[31] J. Morris,et al. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.
[32] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.